Rebiotix: Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. Difficile Infection, as Well as Multiple Analyses Demonstrating Positive Shifts in Microbiome Properties

Press Release: Rebiotix : Ferring and Rebiotix Present Positive Interim Phase 3 Results From Open-Label Study of Investigational Microbiota-Based Live Biotherapeutic RBX2660 at Digestive Disease Week (DDW)

Press Release: Rebiotix : Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection

Rebiotix: Ferring Pharmaceuticals: Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection

Rebiotix: Ferring and Rebiotix to Present Landmark Data for Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week (DDW) 2021

Rebiotix: Ferring, Rebiotix and MyBiotics tackle fertility with microbiome therapeutics for bacterial vaginosis

Rebiotix: Ferring & Rebiotix joins MyBiotics in biotherapeutics deal to address vaginal health